

CURRICULUM VITAE

SCOTT G. FOXMAN, M.D.
Retinal and Ophthalmic Consultants, P.C.

OFFICE LOCATIONS:

1500 Tilton Road, Northfield, NJ 08225

2466 East Chestnut Avenue, Vineland, NJ 08361

211 South Main Street, Cape May Court House, NJ 08210

EDUCATION:

1973 - 1979 B.A. Boston University Medical Honors Program
Boston University

1975-1979 M.D. Boston University Medical Honors Program
Boston University

POSTDOCTORAL RESEARCH:

1979 National Eye Institute

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

1979-1980 Intern in Medicine
Jackson Memorial Hospital

1980-1983 Resident in Ophthalmology
University of Minnesota, Minneapolis

1983-1985 Fellowship, Vitreoretinal Diseases
Jules Stein Eye Institute, UCLA
Los Angeles, California

FACULTY APPOINTMENT:

1983-1985 Visiting Lecturer
Jules Stein Eye Institute
University of California

1986-Present Courtesy
Scheie Eye Institute
University of Pennsylvania School of Medicine

1986-1996 Associate Attending Ophthalmologist
Division of Ophthalmology
AtlantiCare Regional Medical Center

1997-Present Chief, Division of Ophthalmology
AtlantiCare Regional Medical Center

1986-Present Assistant Attending Ophthalmologist
Division of Ophthalmology
Shore Memorial Hospital

SPECIALTY CERTIFICATION:

1979- Diplomat of the National Board of Medical Examiners

1984- Diplomat of the American Board of Ophthalmology

LICENSURE: Pennsylvania, New Jersey, California

PROFESSIONAL SOCIETIES:

National Societies

American Society of Retinal Specialists
American Academy of Ophthalmology
American Medical Association
Association for Research in Vision and Ophthalmology
American Board of Ophthalmology

Local societies

Medical Society of New Jersey
Medical Society of Atlantic County
Academy of Medicine of New Jersey
New Jersey Academy of Ophthalmology
Retina Society of New Jersey

CLINICAL STAFF APPOINTMENTS:

AtlantiCare Regional Medical Center
Shore Memorial Hospital
Scheie Eye Institute

ACADEMIC APPOINTMENTS:

University of Pennsylvania, Courtesy Staff

BOARD POSITIONS:

Past President, Atlantic County Medical Society
Past President, Lions Club Vision Care Center

EDITORIAL POSITION:

Past Business Editor, American Society of Retina Specialists

RESEARCH:

VISTA – Sub-Investigator
Regeneron VGFT-OD-1009
September 2011-Present

A Double-Masked, Randomized, Active-Controlled Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema. PAREXEL #201601

SAKURA-Principal Investigator
Santen Incorporated
June 2011-Present

Protocol No. 32-007: A Phase III, Multinational, Multi-Center, Randomized, Double-Masked Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye.

SHORE-Principal Investigator
Genentech
May 2011-Present

BB-IND 8633-Protocol FVF4967g: A Multi-Center Randomized Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion. April 2011-Present

VIEW 1 EXTENSION - Sub-Investigator
Regeneron
2010-Present

Open-label, long-term, safety and tolerability extension study of intravitreal VEGF Trap-Eye in neovascular age-related macular degeneration

NAION - Principal Investigator
Covance
2009-Present

Prospective case crossover study to assess whether PDE5 inhibitor exposure in men with erectile dysfunction increases the risk for the development of non-arteritic anterior ischemic optic neuropathy (NAION).

HORIZON - Principal Investigator

Genentech
2009-Present
Protocol: FVF3426G

An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or macular edema secondary to retinal vein occlusion (RVO) who have completed a Genentech-sponsored ranizumab study.

COPERNICUS - Sub-Investigator

Regeneron
2009-Present

Randomized, double-masked, controlled phase III study of the efficacy, safety and tolerability of repeated administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO).

HARBOR - Principle Investigator

Genentech
2009-2010

Phase III, double-masked, multi-center, randomized, active treatment, controlled study of the efficacy and safety of 0.5 mg and 2.0 mg Ranibizumab; administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration.

DAVINCI - Sub-investigator

Regeneron
2008-Present

A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema (DME).

RISE - Principal Investigator

Genentech
2008-Present

Three (3) year multi-center study with monthly visits for patients with diabetic macular edema comparing Lucentis with Standard of Care Laser treatments.

CRUISE-Principal Investigator

Genentech
2008-2010

One (1) year multi-center study with monthly visits comparing Lucentis to sham procedure for patients with central retinal vein occlusion.

VIEW1 - Sub-Investigator

Regeneron
2007-Present

Two (2) year multi-center study with monthly visits comparing VEGF-Trap against Lucentis for patients with newly-diagnosed age-related macular degeneration.

SIRIUS - Sub-Investigator

Allergan
2006-2008

Two (2) year multi-center study comparing Sirna against Lucentis for age-related macular degeneration

NOTAL VISION HMP-V4 - Sub-Investigator

Notal Vision
2006-2007

Sensitivity of the Home Macular Perimeter (HMP) in detection of choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD).

SAILOR-Principal Investigator

Genentech, Inc.
2003-2007

One (1) year multi-center study to evaluate the safety and tolerability of Lucentis in newly-diagnosed and previously-treated subjects with age-related macular degeneration.

Visudyne Photodynamic therapy - Sub-Investigator

Ciba Vision
1999-2000

Clinical Investigator for Visudyne Photodynamic Therapy study.

Flibanserin - Sub-Investigator

University of Pennsylvania and Boehringer Ingelheim (BI Trial No. 1997-1998)

Eight (8) week, double-blind, placebo-controlled Phase II study of various doses of flibanserin and paroxetine in patients with Major Depressive Disorder. Our role was to perform ophthalmic examinations to evaluate for potential ocular complications and side effects.

Pioglitazone - Sub-Investigator

Takeda America, Inc.

1996

A double-blind placebo-controlled, randomized, dose-titration study to evaluate the safety and efficacy of pioglitazone, an oral hypoglycemic agent. Our role was to perform retinal examinations and evaluate retinal photographs for evidence of diabetic retinopathy.

Adefovir Dipivoxil (bis-POM PMEA) - Sub-Investigator

NJCRI

1996-1997

A placebo-controlled study of the safety and efficacy of adefovir dipivoxil (bis-POM PMEA) in prolonged survival of HIV-infected individuals with a CD4+ cell count of $\leq 100/\text{mm}^3$. Our role was for ophthalmic evaluation with emphasis on the presence or absence of CMV retinitis.

Silicone Oil - Principal Investigator

Richard James Corporation

1993-1996

Principal Investigator. Clinical investigation as to the utility and safety of silicone oil injection in the vitreous cavity for patients with complicated retinal detachment. Our role was to provide patient care including vitreoretinal surgery.

Perfluorocarbon Liquid - Principal Investigator

Retinal and Ophthalmic Consultants, P.C.

1992-1996

Clinical investigation as to the utility and safety of intra-operative use of perfluorocarbon liquid into the vitreous cavity during surgical reattachment of the retina.

Sulfur hexafluoride and Perfluoropropane - Sub-Investigator

Retinal and Ophthalmic Consultants, P.C.

1989-1994

Clinical investigation as to the utility and safety of long-acting gases in the repair of retinal detachments.

Diabetic Retinopathy

National Institutes of Health

Early Treatment of Diabetic Retinopathy Study (ETDRS)

1984-1985

Dr. Scott Foxman was investigator in landmark national collaborative randomized trial of laser treatment for diabetic retinopathy.

Regeneron Vibrant VGFT e-RVO-1027 – Sub-Investigator
June 2012-Present

A double-masked, randomized, active-controlled study of the efficacy, safety and tolerability of intravitreal administration of VEGF Trap-Eye (Intravitreal aflibercept injection(IAI) in patients with macular edema secondary to branch retinal vein occlusion

DRCR Protocol S – Sub-Investigator
July 2012-Present

Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

PUBLICATIONS:

Original Papers

Ballantine, E., Foxman, S., Gorden, P., Rogh, J.: Rarity of Diabetic Retinopathy in Patients with Acromegaly. Arch. Intern. Med. 1981; 141:1625-1627.

Foxman, S., Cameron, J.D.: The Clinical Implications of Bilateral Microphthalmos with Cyst: Report of a Fatal Case. Am. J. Ophthalmol. 1984; 97:632-638.

Foxman, S., Heckenlively, J., Bateman, J., Wirtschafter, J.: A Classification of Congenital and Early Onset Retinitis Pigmentosa. Arch. Ophthalmol. 1985; 103:1502-1506.

Foxman, S., Heckenlively, J., Sinclair, S.: Pigmented Paravenous Retinochoroidal Atrophy and Rubeola Retinopathy. Am. J. Ophthalmol. 1985; 99:605-606.

Fishman, M., Kerman, B., Foxman, S.: Intraocular Cysticercus: Migratory. Ossonig, K. (ed): Proceedings of the 10th SIDUO Congress, Netherlands, W. Junk, 1986.

Heckenlively, J., Foxman, S., Parelhoff, E.: Retinal Dystrophy and Macular Coloboma. Doc Ophthalmol. 1988:68:257-271.

Shields, J., Perez, N., Shields, C., Foxman, S., Foxman, B.: Simultaneous Choroidal and Brain Metastasis as Initial Manifestations of Lung Cancer. Ophthalmic Surgery and Lasers. 2002:35:323-325.

Foxman, S.: Finding the right fit: Considerations on both sides of the employment process. Retina Times. 2006:24:25-27.

Foxman, S.: Office Administrator: The guide of your practice's success. Retina Times. 2006:24:47-51.

Ferencz L, Lang J, Yeshurn I, Pollack A, Siegel R, Lifshitz T, Karp J et al. Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2010 March.

Brown DM, Campochiaro PA, Singh RP, Li , Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators. Ranibizimab for macular edema following central retinal vein occlusion: Six month primary end-point results of phase III study. Ophthalmology. 2010 June; 117(6):1125-1133.e1.